Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CD4 | P01730 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21595351 | 1.00 | ALDH1A1 (0.40) | ALDH1A1GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL9066820 | 0.77 | GAA (0.47) | ALDH1A1GAAPKMKMT2APOLB | |
| SCHEMBL7849121 | 0.77 | GAA (0.47) | ALDH1A1GAAPKMKMT2APOLB | |
| SCHEMBL9067427 | 0.72 | PKM (0.43) | ALDH1A1GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL9066958 | 0.72 | PKM (0.43) | ALDH1A1GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL9067095 | 0.71 | PKM (0.45) | ALDH1A1GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL9066560 | 0.71 | PKM (0.45) | ALDH1A1GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL9068004 | 0.71 | PKM (0.45) | ALDH1A1GAAPKMKMT2APOLB | |
| SCHEMBL9066498 | 0.71 | PKM (0.45) | ALDH1A1GAASMN1; SMN2PKMKMT2A | |
| SCHEMBL23406562 | 0.70 | PKM (0.44) | ALDH1A1GAAPKMKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-11274111-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME CORP. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3810615-A1 | ARGINASE INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019245890-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163505-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | ALDH1A1 329/4885GAA 120/4885SMN1; SMN2 2243/4885 |
| US-11274111-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | ALDH1A1 329/4885GAA 120/4885SMN1; SMN2 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.